- MetAlert, a developer of personal protective medical equipment and supplies, owes much of its growth to acting on feedback from real-world caregivers who use its products for the monitoring and tracking of vulnerable patients
- This connection with caregivers has yielded advanced products such as the award-winning, multi-patented GPS SmartSole, Invisabelt, Take-Along Tracker, and Rover Tracker, among others
- Attention to consumers has also led to its line of hearing aids, such as its flagship Hear IQ 4 rechargeable, app-controlled hearing aid, and its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space
MetAlert (OTC: MLRT), a developer of personal protective medical equipment and supplies and a pioneer of wearable GPS, human, and asset tracking systems, pays constant and close consideration to feedback from real-world caregivers, and the needs of those who use its products. With over 20 years of experience and an extensive patent portfolio, the company is continually developing viable solutions to individuals afflicted with Alzheimer’s, dementia, and autism (“ADA”), making it one of the few companies that offer practical solutions specific to this group of individuals.
MetAlert is driven by the need to engineer solutions to everyday challenges while maintaining a non-invasive approach to the carrier. This approach has yielded products such as the award-winning, multi-patented GPS SmartSole, the world’s first hidden wearable GPS tracking solution, as well as Invisabelt, Take-Along Tracker, and Rover Tracker, among others. In addition, MetAlert’s Monitoring Portal, accessible via web login, allows caregivers to track those possessing these devices, affording them better care (https://ibn.fm/KY87Z).
General quality-of-life improvements are integral to MetAlert’s overall approach to business. This is evidenced by its line of hearing aids, ranging from its flagship Hear IQ 4 rechargeable, app-controlled hearing aid to its RoomMate wall-mounted 3D sensors for looking after patients without intruding on their personal space. Focusing on such a unique market has allowed the company to grow its market share and reach. It is expected to grow even further in the new year, especially given its recent strategic acquisition of TrakTec LLC.
“It is really about increasing the quality of life, the longevity or people that are challenged,” noted Patrick Bertagna, MetAlert’s CEO (https://ibn.fm/dtMj4).
According to PatSnap, in 2019, over 722 million wearable devices were in use globally, with the number expected to hit one billion by the end of 2023. This, coupled with the fact that non-communicable diseases claim over 41 million lives each year and about 17 million annually before they reach the age of 70, presents a growing need for robust, practical, and effective patient monitoring systems, a need which MetAlert is looking to satisfy (https://ibn.fm/e12Ad). In addition, the growing attention to lifestyle wellness factors creates a market for the company’s products. Its unique approach to their development and marketing sets it apart from its peers, allowing it to impact even more lives as time progresses.
Having had an incredible start to the new year, MetAlert remains committed to growing its platform and range of products and services. It also remains committed to offering solutions with real-world caregivers and businesses in mind, providing resolutions to everyday challenges, and bringing quality-of-life improvements to persons living with ADA.
For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to millions of social media followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
